Evidence map›Paper›PMID 38965372›Full record

ArticleEuropean journal of human genetics : EJHG2024

Burden re-analysis of neurodevelopmental disorder cohorts for prioritization of candidate genes.

Noor Smal, Fatma Majdoub, Katrien Janssens, Edwin Reyniers, Marije E C Meuwissen, Berten Ceulemans, Hope Northrup, Jeremy B Hill, Lingying Liu, Edoardo Errichiello and 17 more

Abstract read
In one paragraph

Article in European journal of human genetics : EJHG, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Noor Smal *Applied and Translational Neurogenomics Group, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium.ORCID http://orcid.org/0000-0003-4335-1583
Fatma Majdoub *Applied and Translational Neurogenomics Group, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium.ORCID http://orcid.org/0009-0001-1175-644X
Katrien JanssensDepartment of Medical Genetics, University of Antwerp, Antwerp, Belgium.
Edwin ReyniersDepartment of Medical Genetics, University of Antwerp, Antwerp, Belgium.
Marije E C MeuwissenDepartment of Medical Genetics, University of Antwerp, Antwerp, Belgium.
Berten CeulemansTranslational Neurosciences, Faculty of Medicine and Health Science, University of Antwerp, Antwerp, Belgium.
Hope NorthrupDepartment of Pediatrics, McGovern Medical School at the University of Texas Health Science Center at Houston (UTHealth) and Children's Memorial Hermann Hospital, Houston, TX, USA.ORCID http://orcid.org/0000-0002-2892-0840
Jeremy B HillDepartment of Pediatrics, McGovern Medical School at the University of Texas Health Science Center at Houston (UTHealth) and Children's Memorial Hermann Hospital, Houston, TX, USA.
Lingying LiuDepartment of Pediatrics, McGovern Medical School at the University of Texas Health Science Center at Houston (UTHealth) and Children's Memorial Hermann Hospital, Houston, TX, USA.
Edoardo ErrichielloDepartment of Molecular Medicine, University of Pavia, Pavia, Italy.ORCID http://orcid.org/0000-0001-6346-1988
Simone GanaNeurogenetics Research Center, IRCCS Mondino Foundation, Pavia, Italy.
Alanna StrongDivision of Human Genetics, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Luis RohenaDivision of Medical Genetics, Department of Pediatrics, San Antonio Military Medical Center, San Antonio, TX, USA.
Rachel FranciskovichDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.
Chaya N MuraliDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.
An HuybrechsDepartment of Pediatrics, Heilig Hart Ziekenhuis, Lier, Belgium.
Telma SulemdeCODE genetics/Amgen Inc., Reykjavik, Iceland.
Run FridriksdottirdeCODE genetics/Amgen Inc., Reykjavik, Iceland.
Patrick SulemdeCODE genetics/Amgen Inc., Reykjavik, Iceland.ORCID http://orcid.org/0000-0001-7123-6123
Kari StefanssondeCODE genetics/Amgen Inc., Reykjavik, Iceland.ORCID http://orcid.org/0000-0003-1676-864X
Yan BaiGeneDx, Gaithersburg, MD, USA.
Jill A RosenfeldDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.ORCID http://orcid.org/0000-0001-5664-7987
Seema R LalaniDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.
Haley StreffDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.
Undiagnosed Diseases Network
R Frank KooyDepartment of Medical Genetics, University of Antwerp, Antwerp, Belgium.ORCID http://orcid.org/0000-0003-2024-0485
Sarah WeckhuysenApplied and Translational Neurogenomics Group, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium. sarah.weckhuysen@uantwerpen.vib.be.ORCID http://orcid.org/0000-0003-2878-1147

Funding

Urine-Derived Cell RNA Sequencing to Improve Diagnosis in Undiagnosed UDN Participants.U01NS134348 · NINDS · BAYLOR COLLEGE OF MEDICINE · PI Carlos A. Bacino, Brendan Lee · 2023 to 2026
$3.8M
EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020) H2020-Twinning SEEDFonds Wetenschappelijk Onderzoek (Research Foundation Flanders) 1861424NFonds Wetenschappelijk Onderzoek (Research Foundation Flanders) G056122NNINDS NIH HHS U01 NS134348Universiteit Antwerpen (University of Antwerp) FFB180186
6 · The paper itself

Abstract

This study aimed to uncover novel genes associated with neurodevelopmental disorders (NDD) by leveraging recent large-scale de novo burden analysis studies to enhance a virtual gene panel used in a diagnostic setting. We re-analyzed historical trio-exome sequencing data from 745 individuals with NDD according to the most recent diagnostic standards, resulting in a cohort of 567 unsolved individuals. Next, we designed a virtual gene panel containing candidate genes from three large de novo burden analysis studies in NDD and prioritized candidate genes by stringent filtering for ultra-rare de novo variants with high pathogenicity scores. Our analysis revealed an increased burden of de novo variants in our selected candidate genes within the unsolved NDD cohort and identified qualifying de novo variants in seven candidate genes: RIF1, CAMK2D, RAB11FIP4, AGO3, PCBP2, LEO1, and VCP. Clinical data were collected from six new individuals with de novo or inherited LEO1 variants and three new individuals with de novo PCBP2 variants. Our findings add additional evidence for LEO1 as a risk gene for autism and intellectual disability. Furthermore, we prioritize PCBP2 as a candidate gene for NDD associated with motor and language delay. In summary, by leveraging de novo burden analysis studies, employing a stringent variant filtering pipeline, and engaging in targeted patient recruitment, our study contributes to the identification of novel genes implicated in NDDs.

Indexed as

Neurodevelopmental DisordersAutistic DisorderChildChild, PreschoolCohort StudiesExome SequencingFemaleHumansIntellectual DisabilityMaleRNA-Binding ProteinsRNA-Binding Proteins

Identifiers

PMID38965372
PMCPMC11577032

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.